Differential effects of lenalidomide during plasma cell differentiation

Oncotarget

Volumn 7, Issue 19, 2016, Pages 28096-28111

  Jourdan, Michel ^a,b   Cren, Maïlys ^a   Schafer, Peter ^c   Robert, Nicolas ^d   Duperray, Christophe ^e   Vincent, Laure ^d   Ceballos, Patrice ^d   Cartron, Guillaume ^d,f   Rossi, Jean François ^d,f   Moreaux, Jérôme ^b,d,f   Chopra, Rajesh ^c   Klein, Bernard ^b,d,f  

^a INSERM   (France)

^b INSTITUTE OF HUMAN GENETICS   (France)

^c CELGENE CORPORATION   (United States)

^d MONTPELLIER UNIVERSITY HOSPITAL   (France)

^e University of Montpellier   (France)

^f UNIV MONTPELLIER   (France)

Author keywords

Differentiation; IKZF1; IKZF3; Lenalidomide; Plasma cell

Indexed keywords

LENALIDOMIDE; ANTINEOPLASTIC AGENT; THALIDOMIDE;

ARTICLE; B LYMPHOCYTE ACTIVATION; B LYMPHOCYTE DIFFERENTIATION; CANCER CHEMOTHERAPY; CELL CYCLE S PHASE; CELL DIFFERENTIATION; CELL DIVISION; CELL POPULATION; CELL PROLIFERATION; CELL SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG DETERMINATION; DRUG EFFECT; HUMAN; HUMAN CELL; MEMORY CELL; MULTIPLE MYELOMA; PLASMA CELL; PLASMABLAST; ANALOGS AND DERIVATIVES; CELL CULTURE; DRUG EFFECTS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; MINIMAL RESIDUAL DISEASE; PATHOLOGY;

ANTINEOPLASTIC AGENTS; CELL DIFFERENTIATION; CELLS, CULTURED; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MULTIPLE MYELOMA; NEOPLASM, RESIDUAL; PLASMA CELLS; THALIDOMIDE;

EID: 84968808314     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.8581     Document Type: Article

References (36)

1. Barlogie B, Desikan R, Eddlemon P, Spencer T, Zeldis J, Munshi N, Badros A, Zangari M, Anaissie E, Epstein J, Shaughnessy J, Ayers D, Spoon D, Tricot G. Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients. Blood. 2001; 98: 492-4.
2. Attal M, Lauwers-Cances V, Marit G, Caillot D, Moreau P, Facon T, Stoppa AM, Hulin C, Benboubker L, Garderet L, Decaux O, Leyvraz S, Vekemans MC, et al. Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. N Engl J Med. 2012; 366: 1782-91.
3. Lacy MQ, McCurdy AR. Pomalidomide. Blood. 2013; 122: 2305-9.
4. Shortt J, Hsu AK, Johnstone RW. Thalidomide-analogue biology: immunological, molecular and epigenetic targets in cancer therapy. Oncogene. 2013; 32: 4191-202.
5. Ito T, Ando H, Suzuki T, Ogura T, Hotta K, Imamura Y, Yamaguchi Y, Handa H. Identification of a primary target of thalidomide teratogenicity. Science. 2010; 327: 1345-50.
6. Zhu YX, Braggio E, Shi C-X, Bruins LA, Schmidt JE, Van Wier S, Chang XB, Bjorklund CC, Fonseca R, Bergsagel PL, Orlowski RZ, Stewart AK. Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide. Blood. 2011; 118: 4771-9.
7. Krönke J, Udeshi ND, Narla A, Grauman P, Hurst SN, McConkey M, Svinkina T, Heckl D, Comer E, Li X, Ciarlo C, Hartman E, Munshi N, et al. Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells. Science. 2014; 343: 301-5.
8. Lu G, Middleton RE, Sun H, Naniong M, Ott CJ, Mitsiades CS, Wong KK, Bradner JE, Kaelin WG. The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins. Science. 2014; 343: 305-9.
9. Gandhi AK, Kang J, Havens CG, Conklin T, Ning Y, Wu L, Ito T, Ando H, Waldman MF, Thakurta A, Klippel A, Handa H, Daniel TO, et al. Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors Ikaros and Aiolos via modulation of the E3 ubiquitin ligase complex CRL4 CRBN. Br J Haematol. 2014; 164: 811-21.
10. Quintana FJ, Jin H, Burns EJ, Nadeau M, Yeste A, Kumar D, Rangachari M, Zhu C, Xiao S, Seavitt J, Georgopoulos K, Kuchroo VK. Aiolos promotes TH17 differentiation by directly silencing Il2 expression. Nature Immunology. 2012; 13: 770-7.
11. Shaffer AL, Emre NCT, Lamy L, Ngo VN, Wright G, Xiao W, Powell J, Dave S, Yu S, Zhao H, Zeng Y, Chen B, Epstein J, Staudt LM. IRF4 addiction in multiple myeloma. Nature. 2008; 454: 226-31.
12. Lopez-Girona A, Heintel D, Zhang L-H, Mendy D, Gaidarova S, Brady H, Bartlett JB, Schafer PH, Schreder M, Bolomsky A, Hilgarth B, Zojer N, Gisslinger H, et al. Lenalidomide downregulates the cell survival factor, interferon regulatory factor-4, providing a potential mechanistic link for predicting response. Br J Haematol. 2011; 154: 325-36.
13. Zhu YX, Braggio E, Shi C-X, Kortuem KM, Bruins LA, Schmidt JE, Chang XB, Langlais P, Luo M, Jedlowski P, Laplant B, Laumann K, Fonseca R, et al. Identification of cereblon-binding proteins and relationship with response and survival after IMiDs in multiple myeloma. Blood. 2014; 124: 536-45.
14. Cortes M. Aiolos Is Required for the Generation of High Affinity Bone Marrow Plasma Cells Responsible for Long-Term Immunity. J Exp Med. 2004; 199: 209-19.
15. Tangye SG. Staying alive: regulation of plasma cell survival. Trends in Immunology. 2011; 32: 595-602.
16. Tarte K, De Vos J, Thykjaer T, Zhan F, Fiol G, Costes V, Reme T, Legouffe E, Rossi JF, Shaughnessy J, Orntoft TF, Klein B Generation of polyclonal plasmablasts from peripheral blood B cells: a normal counterpart of malignant plasmablasts. Blood. 2002; 100: 1113-22.
17. Tangye SG, Avery DT, Hodgkin PD. A division-linked mechanism for the rapid generation of Ig-secreting cells from human memory B cells. J Immunol. 2003; 170: 261-9.
18. Mei HE, Yoshida T, Sime W, Hiepe F, Thiele K, Manz RA, Radbruch A, Dorner T. Blood-borne human plasma cells in steady state are derived from mucosal immune responses. Blood. 2009; 113: 2461-9.
19. Jourdan M, Caraux A, De Vos J, Fiol G, Larroque M, Cognot C, Bret C, Duperray C, Hose D, and Klein B. An in vitro model of differentiation of memory B cells into plasmablasts and plasma cells including detailed phenotypic and molecular characterization. Blood. 2009; 114: 5173-81.
20. Jourdan M, Caraux A, Caron G, Robert N, Fiol G, Reme T, Bollore K, Vendrell JP, Le Gallou S, Mourcin F, De Vos J, Kassambara A, Duperray C, et al. Characterization of a transitional preplasmablast population in the process of human B cell to plasma cell differentiation. J Immunol. 2011; 187: 3931-41.
21. Cocco M, Stephenson S, Care MA, Newton D, Barnes NA, Davison A, Rawstron A, Westhead DR, Doody GM, Tooze RM. In Vitro Generation of Long-lived Human Plasma Cells. J Immunol. 2012; 189: 5773-85.
22. Jourdan M, Cren M, Robert N, Bollore K, Fest T, Duperray C, Guilloton F, Hose D, Tarte K, Klein B. IL-6 supports the generation of human long-lived plasma cells in combination with either APRIL or stromal cell-soluble factors. Leukemia. 2014; 28: 1647-56.
23. Caraux A, Klein B, Paiva B, Bret C, Schmitz A, Fuhler GM, Bos NA, Johnsen HE, Orfao A, Perez-Andres M for the Myeloma Stem Cell Network (MSCNET). Circulating human B and plasma cells. Age-associated changes in counts and detailed characterization of circulating normal CD138-and CD138+ plasma cells. Haematologica. 2010; 95: 1016-20.
24. Chen N, Lau H, Kong L, Kumar G, Zeldis JB, Knight R, Laskin OL. Pharmacokinetics of lenalidomide in subjects with various degrees of renal impairment and in subjects on hemodialysis. J Clin Pharmacol. 2007; 47: 1466-75.
25. Escoubet-Lozach L, Lin I-L, Jensen-Pergakes K, Brady HA, Gandhi AK, Schafer PH, Muller GW, Worland PJ, Chan KWH, Verhelle D. Pomalidomide and lenalidomide induce p21 WAF-1 expression in both lymphoma and multiple myeloma through a LSD1-mediated epigenetic mechanism. Cancer Res. 2009; 69: 7347-56.
26. Huff CA, Matsui W. Multiple myeloma cancer stem cells. J Clin Oncol. 2008; 26: 2895-900.
27. Kim D, Park CY, Medeiros BC, Weissman IL. CD19-CD45 low/-CD38 high/CD138+ plasma cells enrich for human tumorigenic myeloma cells. Leukemia. 2012; 26: 2530-7.
28. Leung-Hagesteijn C, Erdmann N, Cheung G, Keats JJ, Stewart AK, Reece DE, Chung KC, Tiedemann RE. Xbp1s-negative tumor B cells and pre-plasmablasts mediate therapeutic proteasome inhibitor resistance in multiple myeloma. Cancer Cell. 2013; 24: 289-304.
29. Caraux A, Vincent L, Bouhya S, Quittet P, Moreaux J, Requirand G, Veyrune JL, Olivier G, Cartron G, Rossi JF, Klein B. Residual malignant and normal plasma cells shortly after high dose melphalan and stem cell transplantation. Highlight of a putative therapeutic window in Multiple Myeloma? Oncotarget. 2012; 3: 1335-47. doi: 10.18632/oncotarget.650.
30. Amé-Thomas P, Maby-El Hajjami H, Monvoisin C, Jean R, Monnier D, Caulet-Maugendre S, Guillaudeux T, Lamy T, Fest T, Tarte K. Human mesenchymal stem cells isolated from bone marrow and lymphoid organs support tumor B-cell growth: role of stromal cells in follicular lymphoma pathogenesis. Blood. 2007; 109: 693-702.
31. Quah BJ, Warren HS, Parish CR. Monitoring lymphocyte proliferation in vitro and in vivo with the intracellular fluorescent dye carboxyfluorescein diacetate succinimidyl ester. Nat Protoc. 2006; 2: 2049-56.
32. Paiva B, Almeida J, Pérez-Andrés M, Mateo G, López A, Rasillo A, Vídriales MB, López-Berges MC, San Miguel JF, Orfao A. Utility of flow cytometry immunophenotyping in multiple myeloma and other clonal plasma cell-related disorders. Cytometry B Clin Cytom. 2010; 78: 239-52.
33. Klein B, Seckinger A, Moehler T, Hose D. Molecular pathogenesis of multiple myeloma: chromosomal aberrations, changes in gene expression, cytokine networks, and the bone marrow microenvironment. Recent Results Cancer Res. 2011; 183: 39-86.
34. Podar K, Chauhan D, Anderson KC. Bone marrow microenvironment and the identification of new targets for myeloma therapy. Leukemia. 2009; 23: 10-24.
35. Ria R, Todoerti K, Berardi S, Coluccia AML, De Luisi A, Mattioli M, Ronchetti D, Morabito F, Guarini A, Petrucci MT, Dammacco F, Ribatti D, Neri A, Vacca A. Gene expression profiling of bone marrow endothelial cells in patients with multiple myeloma. Clin Cancer Res. 2009; 15: 5369-78.
36. Domingo E, Moreno C, Sánchez-Ibarrola A, Panizo C, Páramo JA, Merino J. Enhanced sensitivity of flow cytometry for routine assessment of minimal residual disease. Haematologica. 2010; 95: 691-2.